Best Research Poster Presentation Award

GENERAL (up to 3 awards each conference)

NEW INVESTIGATOR (up to 3 awards each conference)

STUDENT (up to 3 awards each conference)

Background provides appropriate perspective / context for the subject

Objectives / research questions are clearly stated

Research design / methods / modeling is appropriate and transparent {scores on this will determine winners in case of ties}

Data sources and/or sampling procedures are clear and appropriate

Data analyses are appropriate

Research objectives are met/addressed

Factual information is kept separate from interpretations or implications

Abstract is presented in an unbiased manner

Clarity of presentation

Poster Presentations considered:

The top 10% of scores given by the Contributed Research Review Committee at the time of submission are considered for the award.

3 weeks prior to conference, select preconference registrants are invited to participate to judge poster presentations

Judges are asked to select their field of interest

Judges are assigned presentations according to their field of interest

Each judge evaluates their assigned posters

All posters are judged equally regardless of categories. Judges do not know whether the presentation is Student, New Investigator or General

Judge's scores are compiled, per category, and talleyed to get the overall score

Committee Chair(s) determine the recipients of the awards (up to 3in each category)

A certificate with an inscription stating the award name, name of the presenting author, and title of the presentation shall be sent to the award recipient after the meeting or congress when the conditions of acceptance are met.

To receive the award, the awardee must submit the poster presentation for which the award is given for publication at the website, along with author permission. Failure to submit the poster PDF and permission within the designated timeframe will result in forfeiture of award.

Official announcement of the recipients will occur after the conference via Value & Outcomes Spotlight, eBulletin, the website, and an email to conference attendees.

Best General Poster Research Presentations

Comparison of Costs Associated With TURP and Prostatic Urethral Lift for Benign Prostatic Hyperplasia [PUK20]

Andrzei Orlowski, Imperial College Health Partners, London, UK

Inpatient Admission Length of Stay and Costs Among Vascular Procedure Patients Receiving Perclose Proglide Suture-Mediated Closure Compared to Patients Receiving Surgical Cutdown for Closure of Large Bore Arterial Access [PCV61]

Ellen R. Thiel, Truven Health Analytics, an IBM Company, Cambridge, MA, USA

Treatment With Prostacyclins Delays and Reduces Hospital Readmissions Among PAH Patients [PSY107]

Peter Classi, United Therapeutics, Durham, NC, USA

Best Student Poster Research Presentations

Economic Burden of Renal Cell Carcinoma Among Older Adults in the Targeted Therapy Era [PCN212]

Hrishikesh P. Kale, Virginia Commonwealth University, Richmond, VA, USA

Association Between Hydroxyurea Medication Adherence and Vaso-Occlusive Crisis Events Among Texas Medicaid Enrollees With Sickle Cell Disease [PSY63]

Hyeun Ah Kang, The University of Texas at Austin, Austin, TX, USA

Comparative Effectiveness of Apixaban Versus Warfarin for the Prevention of Recurrent Venous Thromboembolism and Cardiovascular Diseases in Patients With Venous Thromboembolism [PCV20]

Ghadeer Dawwas, University of Florida, Gainesville, FL, USA

Best New Investigator Poster Research Presentations

Predictors and Incidence of Cardiovascular Events in Patients With Rheumatoid Arthritis [PMS9]

Elmor D Pineda, Baylor Scott & White Health, Temple, TX, USA

Prescription Opioid Use Among Children and Adolescents With Asthma in the United States: National Estimates From 2011 to 2015 [PRS41]

Saurabh P Nagar, RTI Health Solutions, Research Triangle Park, NC, USA

Real-World Outcomes and Medication Adherence to Disease Modifying Therapies Among Patients With Multiple Sclerosis [PND8]

Dante M. Grassi, Geisinger, Danville, PA, USA

Best General Poster Research Presentations

PDB68 - PSYCHOMETRIC EVALUATION OF THE NV QUESTIONNAIRE IN PATIENTS WITH T2DM RECEIVING A GLP-1 AGONIST

McLeod L¹, Sikirica MV², Qin S¹, Joshi AV², Sweeney CT¹, Blum SI^2
1RTI Health Solutions, Research Triangle Park, NC, USA, ²GlaxoSmithKline, Collegeville, PA, USA

PCN254 - DO ADVANCES IN BREAST CANCER TREATMENT RENDER SCREENING MAMMOGRAPHY NOT COST-EFFECTIVE FOR AVERAGE-RISK WOMEN?

Shen Y¹, Dong W¹, Xu Y², Shih YT^2
1UT MD Anderson Cancer Center, Houston, TX, USA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Best Student Poster Research Presentations

PCV16 - FONDAPARINUX SODIUM COMPARED WITH LOW MOLECULAR WEIGHT HEPARINS FOR THROMBOPROPHYLAXIS AMONG PATIENTS AT RISK AS PER VIRCHOW’S TRIAD: A SYSTEMATIC REVIEW AND META ANALYSIS

Kumar A, Talwar A, Wu W
College of Pharmacy and Health Sciences, St. John's University, New York, NY, USA

PIH4 - REPEAT ADVERSE DRUG REACTION-RELATED HOSPITAL ADMISSIONS IN ELDERLY AUSTRALIANS

Parameswaran Nair N¹, Chalmers L¹, Bereznicki B¹, Curtain C¹, Connolly M², Bereznicki L^1
1University of Tasmania, Hobart, Australia, ²Royal Hobart Hospital, Hobart, Australia

PGI1 - RISK OF CLOSTRIDIUM DIFFICILE INFECTION ASSOCIATED WITH PROTON PUMP INHIBITOR USE AMONG COMMUNITY DWELLING ADULTS WITH GASTROESOPHAGEAL REFLUX DISEASE

Rane P¹, Guha S², Garey K¹, Chen H¹, Johnson ML³, Aparasu RR^3
1University of Houston, Houston, TX, USA, ²University of Texas Health Science Center, Houston, TX, USA, ³College of Pharmacy, University of Houston, Houston, TX, USA

Best New Investigator Poster Research Presentations

PND25 - INCREMENTAL ECONOMIC BURDEN OF CARDIOMETABOLIC DISORDERS AMONG PATIENTS WITH EPILEPSY

Ajmera MR, Goyal RK, Davis KL
RTI Health Solutions, Research Triangle Park, NC, USA

PCN79 - HEALTHCARE EXPENDITURES AMONG COMMUNITY-DWELLING ADULTS WITH THYROID CANCER IN THE UNITED STATES: A PROPENSITY SCORE MATCHED ANALYSIS

Bhattacharjee S¹, Khobrani M¹, Alrabiah Z¹, Bilal J², Riaz I^{3 1}The University of Arizona, Tucson, AZ, USA,²The University of Arizona, College of Medicine, Tucson, AZ, USA, ³University of Arizona, Tucson, AZ, USA

PCV95 - PROJECTED IMPACT OF ADOPTING A MULTIPLEXED PREEMPTIVE GENOTYPING INTERVENTION IN CARDIAC CATHETERIZATION LABORATORY PATIENTS

Wiltshire T¹, Dong O¹, Li A¹, Suzuki O¹, Oni-Orisan A², Stouffer G¹, Lee C^1
1University of North Carolina, Chapel Hill, NC, USA, ²University of California, San Francisco, CA, USA

Best General Poster Research Presentations 

PMS38 - HEALTH CARE RESOURCE UTILIZATION AND DIRECT MEDICAL COST FOR INPATIENTS WITH OSTEOPOROTIC FRACTURE IN TIANJIN, CHINA

Qu Y¹, Wang K², Chen Y², Wu J1
¹Tianjin University, Tianjin, China, ²Lilly Suzhou Pharmaceutical Company, Ltd., Shanghai, China

It is the first study using a claims database to quantitatively report the one-year direct healthcare burden after an osteoporotic fracture in China.

PIN52 - EVALUATION OF THE PERFORMANCE PROPERTIES OF THE INFLUENZA PATIENT-REPORTED OUTCOMES INSTRUMENT (FLU-PRO)

Powers JH¹, Bacci ED², Leidy NK³, Stringer S³, Kim K³, Memoli MJ⁴, Han A⁴, Fairchok MP⁵, Chen W⁶, Arnold JC⁷, Danaher PJ⁸, Lalani T⁹, Hansen EA¹⁰, Ridore M¹¹, Burgess TH⁶, Millar EV⁶, Hernández A¹², Rodríguez-Zulueta P¹³, Ortega-Gallegos H¹⁴, Galindo-Fraga A¹⁴, Ruiz-Palacios GM¹⁴, Pett S¹⁵, Fischer W¹⁶, Gillor D¹⁷, Macias LM¹⁸, DuVal A¹⁹, Rothman R¹⁹, Dugas A¹⁹, Guerrero ML^14
1Leidos Biomedical Research in support of NIH, George Washington University School of Medicine, Rockville, MD, USA, ²Evidera, Seattle, WA, USA, ³Evidera, Bethesda, MD, USA, ⁴National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, ⁵Madigan Army Medical Center; Infectious Disease Clinical Research Program, Uniformed Services University, Tacoma, WA, USA, ⁶Infectious Disease Clinical Research Program, Uniformed Services University, Rockville, MD, USA, ⁷Naval Medical Center, San Diego, CA, USA, 8Air Force Medical Operations Agency (AFMOA), Lackland, TX, USA, ⁹Naval Medical Center Portsmouth, VA; Infectious Disease Clinical Research Program, Uniformed Services University, Portsmouth, VA, USA, ¹⁰Operational Infectious Diseases, Naval Health Research Center, San Diego, CA, USA, ¹¹Children’s National Medical Center, Washington, DC, USA, ¹²Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico, ¹³Hospital General Dr. Manuel Gea González, Ciudad de México, Mexico, ¹⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Ciudad de Mexico, Mexico, ¹⁵University College London, London, UK, ¹⁶The University of North Carolina School of Medicine, Chapel Hill, NC, USA, ¹⁷University Hospital of Cologne, Köln, Germany, ¹⁸Hospital General de Agudos JM Ramos Mejia Servicio de Inmunocomprometidos, Buenos Aires, Argentina, ¹⁹Johns Hopkins University School of Medicine, Baltimore, MD, USA

The FLU PRO patient reported outcome scale for evaluating symptoms in influenza is a comprehensive instrument developed using best scientific methods for PRO development, for use in clinical trials and epidemiology studies of influenza. There is a need for accurate, reliable and comprehensive outcome measures in influenza and other viral illnesses in both hospitalized patients and outpatients and FLU PRO is a step in that direction. Moreover, FLU PRO represents the efforts of multiple networks and funding streams to develop the instrument, including investigators from the Department of Defense/Infectious Diseases Clinical Research Program, the LaRed Emerging Infectious Diseases Network in Mexico, the multinational INSIGHT network, Johns Hopkins University and the NIH clinical center with funding from NIH, BARDA and FDA.

PHS32 - CLINICAL AND ECONOMIC BURDEN OF BLOODSTREAM INFECTIONS FOLLOWING CENTRAL VENOUS CATHETER PLACEMENT IN THE INTENSIVE CARE UNIT

Brunelli SM¹, Turenne W¹, Sibbel S¹, Hunt A¹, Pfaffle A^2
1DaVita Clinical Research, Minneapolis, MN, USA, ²CorMedix Inc, Bedminster, NJ, USA

These data highlight both the humanistic and economic burden imposed by central venous catheter related blood stream infections in the ICU and further the imperative for developing effective preventative measures.

Best Student Poster Research Presentations

PIN38 - EXPLORING THE COST-EFFECTIVE THRESHOLD PRICE OF DENGUE VACCINATION PROGRAMS IN MALAYSIA: A VALUE-BASED PRICING ASSESSMENT

Yeo HY¹, Shafie AA¹, Coudeville L², Steinberg LD³, Gill BS⁴, Jahis R^4
1Universiti Sains Malaysia, Penang, Malaysia, ²Sanofi Pasteur, Lyon, France, ³Sanofi Pasteur, Petaling Jaya, Malaysia, ⁴Ministry of Health Malaysia, Wilayah Persekutuan Putrajaya, Malaysia

PMH39 - COST EFFECTIVENESS OF LURASIDONE, QUETIAPINE, AND OLANZAPINE MONOTHERAPY IN THE TREATMENT OF BIPOLAR I DISORDER DEPRESSION

Bhagvandas NS, Hay JW
University of Southern California, Los Angeles, CA, USA

My presentation focuses on monotherapy in bipolar depression as there is almost always greater compliance when there is only a single medication involved and my study shows that Lurasidone could be a cost-effective option in the treatment of bipolar depression.

PCN203 - EVALUATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER: SYSTEMATIC REVIEW AND TRIAL LEVEL META-ANALYSIS

Adunlin G¹, Dranitsaris G^2
1Virginia Commonwealth University, Richmond, VA, USA, ²Augmentium Pharma Consulting Inc., Toronto, ON, Canada

Progression free survival can be a suitable surrogate for overall survival in trials evaluating new treatments in the 2nd setting and beyond, while it is of limited clinical value in the 1st line setting and should be supplemented with meaningful patient reported outcome measures such as improvements in performance status, symptom control, and weight gain.

Best New Investigator Poster Research Presentations

PHS102 - CHARACTERIZING EMERGENCY DEPARTMENT UTILIZATION AMONG PEDIATRIC PATIENTS WITH TYMPANOSTOMY TUBES

Tam IM¹, Candrilli SD², Moss JR^3
1Otonomy, Inc., San Diego, CA, USA, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³Charlotte Eye, Ear, Nose, and Throat Associates, Matthews, NC, USA

This large US claims database study showed that Medicaid-enrolled pediatric patients utilized emergency department (ED) services, for all cause and ear-related diagnoses, significantly more often than those with Commercial insurance during the 360 days after tympanostomy tube placement, the most common ambulatory surgery performed in children, indicating a need for better access to appropriate levels of care for the Medicaid population and education of caregivers on appropriate follow-up care.

PRM106 - VALUE OF INFORMATION METHODS FOR OPTIMAL TIMING OF BIOMARKER COLLECTION

Bansal A, Basu A
University of Washington, Seattle, WA, USA

PRS55 - RELATIONSHIP BETWEEN SEVERITY AND ACUTE INHALER USE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Hur P¹, Albrecht J², Huang T³, Simoni-Wastila L³, Moyo P³, Khokhar B³, Harris I⁴, Wei Y^5
1University of Maryland School of Pharmacy, Baltimore, MD, USA, ²Univeristy of Maryland, School of Medicine, Baltimore, MD, USA, ³Univeristy of Maryland, School of Pharmacy, Baltimore, MD, USA, ⁴Impaq International, Columbia, MD, USA, ⁵University of Florida College of Pharmacy, Gainesville, FL, USA

This study was looking at the influence of COPD severity on acute inhaler use to bring awareness and potentially improve patient outcomes.

Best General Poster Research Presentations

PND7 - TOTAL MIGRAINE FREEDOM FOR BREATH POWERED INTRANASAL DELIVERY OF 22 MG SUMATRIPTAN POWDER (AVP-825) VERSUS 100 MG ORAL SUMATRIPTAN FROM THE COMPASS STUDY OF ACUTE TREATMENT OF MIGRAINE

Halker R¹, Tepper S², Siegert S³, Wallick C^3
1Mayo Clinic Phoenix, Scottsdale, AZ, USA, ²Cleveland Clinic, Cleveland, OH, USA, ³Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA

PND63 - THE EVALUATION OF WORK PRODUCTIVITY IN RELAPSING-REMITTING (RRMS) AND SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) PATIENTS IN EUROPE

Pike J¹, Naoshy S², Watson C², Jones E^1
1Adelphi Real World, Manchester, UK, ²Biogen Idec, Cambridge, MA, USA

PRM79 - DEVELOPMENT AND VALIDATION OF THE HEMOPHILIA-SPECIFIC BURDEN SCALE FOR CAREGIVERS OF CHILDREN WITH HEMOPHILIA IN THE US – THE HEMOPHILIA ASSOCIATED CAREGIVER BURDEN SCALE (HEMOCABTM)

von Mackensen S¹, Wisniewski T², Urgo J³, Boggio L^3
1University Medical Center, Hamburg, Germany, ²NOVO Nordisk, Plainsboro, NJ, USA, ³RUSH University Medical Centre, Chicago, IL, USA

Best Student Poster Research Presentations

PHS62 - COST-EFFECTIVENESS OF A BEHAVIORAL PSYCHOSOCIAL TREATMENT INTEGRATED ACROSS HOME AND SCHOOL FOR PEDIATRIC ADHD-INATTENTIVE TYPE

Tran JL, Sheng R, Esonwune-Chukwudi P, Beaulieu A, McBurnett K, Pfiffner LJ, Wilson L
University of California, San Francisco, San Francisco, CA, USA

PCV8 - COMPARATIVE EFFECTIVENESS OF RIVAROXABAN AND STANDARD ANTICOAGULANT THERAPIES FOR PREVENTION OF PRIMARY VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY

Shewale AR, Martin BC
University of Arkansas for Medical Sciences, Little Rock, AR, USA

PDB93 - DOES TREATMENT FOR NEWLY-DIAGNOSED DEPRESSION REDUCE HEALTHCARE EXPENDITURES AMONG MEDICAID BENEFICIARIES WITH TYPE 2 DIABETES MELLITUS?

Bhattacharya R¹, Wachholtz A², Dwibedi N³, Misra R³, Scott V³, Sambamoorthi U^3
1West Virginia University, Tucson, AZ, USA, ²University of Massachusetts, North Worcester, MA, USA, ³West Virginia University, Morgantown, WV, USA

Best New Investigator Poster Research Presentations

PHP82 - IMPACT OF CLINICAL AND HEALTH ECONOMIC PUBLICATIONS ON COMMERCIAL SUCCESS OF PHARMACEUTICAL PRODUCTS IN THE U.S

Slejko JF¹, Basu A², Sullivan SD^3
1University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Washington, Seattle, WA, USA, ³University of Washington School of Pharmacy, Seattle, WA, USA

PDB5 - PREDICTING CHRONIC COMORBID CONDITIONS OF TYPE 2 DIABETES IN NEWLY-DIAGNOSED DIABETIC PATIENTS

Razavian N¹, Smith-McLallen A², Nigam S², Blecker S¹, Schmidt AM¹, Sontag D^1
1New York University, New York City, NY, USA, ²Independence Blue Cross, Philadelphia, PA, USA

PHS174 - OUTPATIENT FOLLOW-UP VISITS AFTER HOSPITAL DISCHARGE FOR MENTAL ILLNESS AND IMPLICATIONS FOR RE-ADMISSIONS

Lin I¹, Muser E², Munsell M¹, Menzin J^1
1Boston Health Economics, Inc., Waltham, MA, USA, ²Janssen Scientific Affairs, LLC, Titusville, NJ, USA

Best General Poster Research Presentations

PMH34: THE BURDEN OF OPIOID ABUSE AMONG COMMERCIALLY-INSURED PATIENTS

Rice JB¹, Kirson NY¹, Shei A¹, Enloe C¹, Cummings AK¹, Birnbaum HG¹, Ben-Joseph R^2
1Analysis Group, Inc., Boston, MA, USA, ²Purdue Pharma L.P., Stamford, CT, USA

PND29: HOSPITAL-BASED UTILIZATION IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME

Belk KW, Craver CW
MedAssets, Charlotte, NC, USA

PSY43: PSYCHOMETRIC PROPERTIES OF THE ADHD RATING SCALE-IV (ADHD RS-IV) AND ADULT ADHD SELF-REPORT SCALE (ASRS) IN A PHASE 3B CLINICAL TRIAL OF PATIENTS WITH PHENYLKETONURIA

Wyrwich KW¹, Auguste P¹, Yu R¹, Zhang C², Yu S², DeWees B², Winslow B², Merilainen M², Prasad S^2
1Evidera, Bethesda, MD, USA, ²BioMarin Pharmaceutical Inc., Novato, CA, USA

Best Student Poster Research Presentations

PHP32: COMMUNITY PHARMACIST CHARACTERISTICS ASSOCIATED WITH USE OF A PRESCRIPTION DRUG MONITORING PROGRAM

Wixson SE, Blumenschein K, Goodin AJ, Talbert J, Freeman PR
University of Kentucky, Lexington, KY, USA

PHP42: TRENDS IN MEDICAID FEE-FOR-SERVICE OUTPATIENT DRUG UTILIZATION, EXPENDITURES AND PHARMACY REIMBURSEMENT RATES (2010-2012)

Balkhi B¹, Alshehri A¹, Szeinbach SL², Seoane-Vazquez E^1
1International Center for Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, ²Ohio State University, Columbus, OH, USA

PHS29: ASSESSING THE ECONOMIC BURDEN OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER AMONG CHILDREN IN THE UNITED STATES USING THE 2011 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

Gupte KP, Singh RR, Lawson KA
The University of Texas at Austin, Austin, TX, USA

Best New Investigator Poster Research Presentations

PHS51: COST-EFFECTIVENESS ANALYSIS OF GOVERNMENT INSURED ROUTINE EYE EXAMINATION: EVIDENCE FROM PRINCE EDWARDS ISLAND, CANADA

Thavorn K¹, Tu HA², Wedge R³, Jin Y², Trope G², El-Defrawy S⁴, Flanagan J⁵, Buys YM^2
1St.Michael's Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Health PEI, Charlottetown, PE, Canada, ⁴Kensington Eye Institute, Toronto, ON, Canada, ⁵University of Toronto, ON, Canada

PRM78: A COMPARISON OF THE UTILITY OF VARIANTS OF THE CHARLSON COMORBIDITY INDEX (CCI) IN PREDICTING PATIENT-REPORTED HEALTH OUTCOMES

Witt EA¹, Goren A^2
1Kantar Health, Princeton, NJ, USA, ²Kantar Health, New York, NY, USA

PHS119: PROVISION OF CULTURAL COMPETENCY TRAINING IN THE NATIONAL HOME AND HOSPICE CARE SURVEY: THE ROLE OF ORGANIZATIONAL AND LEADERSHIP FACTORS

AbuDagga A¹, Khasawinah S², Weech-Maldonado R³, Tian F^4
1Public Citizen, Washington DC, DC, USA, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, DC, USA, ³University of Alabama at Birmingham, Birmingham, AL, USA, ⁴HealthCore Inc., Alexandria, VA, USA

Best General Poster Presentations

Clare Jones

Php31: Impact Of European Medicines Agency (Ema) Clinical Trial Transparency Policies On Health Technology Assessment (Hta) Decisions In Germany

Mohit Kumar Bhutani

Pms1:Comparative Effectiveness Of Baricitinib Versus Sarilumab In Rheumatoid Arthritis: A Systematic Review And Network Meta-Analysis

Lieven Annemans

Pcv96: Healthcare Resource Utlisation In Patients On Lipid-Lowering Therapies Outside Of Western Europe: Findings Of The International Cholesterol Management Practice Study (Iclps)

Asia Sikora Kessler

Pnd150: Impact Of Inotersen On Condition-Specific Quality Of Life (Qol) For Patients With Hattr Amyloidosis: Results From A Double-Blind Placebo-Controlled Trial

Best Student Poster Research Presentations

Frederick Thielen

Psy80: The Cost Of Healthcare For Children With Sickle Cell Disease: An Analysis Of Healthcare Utilization And Expenditures In The Netherlands

Xue Han

Pcv131:Impact Of Timely Initiation Of Antihypertensive Medications For Patients With Hypertension Or Elevated Blood Pressure

Saeed Taheri

Pih7:Long-Acting Recombinant FSH (Corifollitropin Alfa) Versus Recombinant FSH As Assisted Reproduction Techniques In The Management Of Infertility: A Systematic Review And Meta-Analysis

Best New Investigator Poster Research Presentations

Ejike Nwokoro

Php213: A Retrospective Review Of Reimbursement Decisions By The Haute Autorité De Santé In 2017 - Underlying Rationale For Medicinal Products With Insufficient Actual Medical Benefit

Matthew Walton

Php273: A Review Of Issues Affecting The Efficiency Of Decision Making In The Nice Single Technology Appraisal Process

Taneesha Chawla

Pcn293: What Is The Value Of Real World Evidence In Oncology In Hta Appraisals In England, France, Canada And Australia?

Best General Poster Research Presentations

PCN177: COST UTILITY ANALYSIS (CUA) OF NIVOLUMAB COMPARED TO EVEROLIMUS FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (RCC) IN AUSTRALIA

Hansoo Kim
Bristol-Myers Squibb Australia, Mulgrave, Australia

PMS13: RISK OF MAJOR OSTEOPOROTIC FRACTURE (HIP, VERTEBRAL, RADIUS, HUMERUS [MOF]) AFTER FIRST, SECOND AND THIRD FRAGILITY FRACTURE IN A SWEDISH GENERAL POPULATION COHORT

Emma Jonsson
Quantify Research, Stockholm, Sweden

PMD58: CONTINUOUS SUBCUTANEOUS INFUSION VERSUS MULTIPLE DOSE INJECTION OF INSULIN FOR NEWLY-DIAGNOSED T1D PAEDIATRIC PATIENTS: A COST-UTILITY ANALYSIS

Colin H. Ridyard
Bangor University, Bangor, UK

Best Student Poster Research Presentations

PCN249: SUBJECTIVE FINANCIAL BURDEN AMONG GERMAN CANCER PATIENTS - RELATIONSHIP OF THE PATIENTS' ECONOMIC SITUATION AND SUBJECTIVE DISTRESS

Julian Witte
Bielefeld University, School of Public Health, Bielefeld, Germany

PMH28: INTERNET BASED TREATMENT OF DEPRESSIVE SYMPTOMS – A HEALTH ECONOMIC EVALUATION OF COSTS AND BENEFITS

Viola Gräfe
School of Public Health, Bielefeld University, Bielefeld, Germany

PSY43: BURDEN OF RENAL TRANSPLANT AMONG A COHORT OF US MEDICARE BENEFICIARIES WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Laura A. Clark
University of North Carolina at Charlotte, Charlotte, NC, USA

Best New Investigator Poster Research Presentations

PCV34: SURVIVAL DIFFERENCES IN HEART FAILURE PATIENTS WITH AND WITHOUT IRON DEFICIENCY/ANEMIA AND BY ORAL AND INTRAVENOUS IRON TREATMENT

Julia Altevers
Xcenda GmbH, Hannover, Germany

PMD156: DOES THE NICE DIAGNOSTICS ASSESSMENT PROGRAMME USE AN EMPIRICAL ICER THRESHOLD?

Gengshi Chen
Costello Medical Consulting Ltd, Cambridge, UK

PRM157: PREDICTING EQ-5D INDEX SCORES FROM PROMIS PROFILE 29 IN THE UNITED KINGDOM, FRANCE, AND GERMANY

Christoph Paul Klapproth
Charité Universitätsmedizin Berlin, Berlin, Germany

Best General Poster Research Presentations

PRM143-QUALITY OF LIFE OF PATIENTS TREATED FOR MULTIPLE MYELOMA (MM) IN FRANCE IN A REAL-WORLD SETTING

Despiegel N¹, Touboul C², Flinois A², Saba G², Gonzalez-McQuire S³, Suzan F³, Blachier-Poisson C¹, Guilhaume C^1
1Amgen France, Paris, France, ²Kantar Health, Paris, France, ³Amgen (Europe) GmbH, Zug, Switzerland

This study aims at measuring the health related quality of life in multiple myeloma in the real life setting. It shows that quality of life worsens with disease progression especially when patients are treated with best supportive care. This study is very important to confirm the high burden of multiple myeloma from a patient perspective.

PGI8-RATE AND HEALTHCARE UTILIZATION (LOS AND COSTS) OF ADHESION RELATED COMPLICATIONS AFTER COLON RESECTION PROCEDURES

Etter K¹, Sutton N², Wei D³, Yoo A^1
1Johnson & Johnson Co., New Brunswick, NJ, USA, ²Johnson & Johnson Medical Devices, Somerville, NJ, USA, ³Johnson & Johnson Co., Raleigh, NC, USA

This study utilized Truven MarketScan® Commercial and Medicare (2009 to 2013) data to explore adhesion related complications (ARC) within one year after colon resection procedures, with a focus on ARC incidence and associated economic burden.

PSY69-COST-EFFECTIVENESS ANALYSIS OF IBRUTINIB FOR WALDENSTRÖM MACROGLOBULINEMIA IN ITALY

Aiello A¹, D'Ausilio A¹, Randon F², Lo Muto R^2
1Creativ Ceutical, Milano, Italy, ²Janssen-Cilag, Cologno Monzese, Italy

Best Student Poster Research Presentations

PMH48-FEASIBILITY, RELIABILITY AND VALIDITY OF THE DECISION TOOL UNIPOLAR DEPRESSION (DTUD) IN IDENTIFYING PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN NEED OF HIGHLY SPECIALIZED CARE

van Krugten FC¹, Kaddouri M¹, Goorden M¹, van Balkom AJ², Ruhé HG³, van Schaik DJ², van Oppen P², Hakkaart-van Roijen L^1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, ²VU University Medical Centre, Amsterdam, The Netherlands, ³University Medical Centre Groningen, Groningen, The Netherlands

The focus in this presentation is on the psychometric properties of a tool for the early identification of patients with MDD in need of highly specialized care.

PHP96-COST OF LOST PRODUCTIVITY DUE TO PREMATURE, SUICIDE-RELATED MORTALITY IN POLAND

Orlewska K
Medical University of Warsaw, Warsaw, Poland

PMS43-A COST-EFFECTIVENESS ANALYSIS OF ABATACEPT, TOCILIZUMAB, AND TNF-INHIBITOR COMPARED WITH RITUXIMAB AS A SECOND-LINE THERAPY FOR TREATMENT OF RHEUMATOID ARTHRITIS

Huoponen S¹, Aaltonen KJ¹, Joensuu JT¹, Rutanen J², Relas H³, Taimen K⁴, Puolakka K⁵, Sokka T⁶, Nordström D³, Blom M^1
1University of Helsinki, Helsinki, Finland, ²Lahti Central Hospital, Lahti, Finland, ³Helsinki University Central Hospital, Helsinki, Finland, ⁴Turku University Central Hospital, Turku, Finland, ⁵South Karelia Central Hospital, Lappeenranta, Finland, ⁶Jyväskylä Central Hospital, Jyväskylä, Finland

This patient-level simulation model evaluated the cost-effectiveness of abatacept, tocilizumab, and TNF-inhibitors in comparison to rituximab as a second-line biologic therapy in rheumatoid arthritis using the Finnish registry data.

Best New Investigator Poster Research Presentations

PDB92-CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON BASAL INSULIN REGIMENS: RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORD DATA

Lee LK¹, Liebert R², Hallissey B^3
1Kantar Health, Foster City, CA, USA, ²Kantar Health, New York, NY, USA, ³Kantar Health, Horsham, PA, USA

PCN157-ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT OF WOMEN WITH HER2-POSITIVE, LOCALLY ADVANCED, INFLAMMATORY OR EARLY BREAST CANCER IN PORTUGAL

Ribeiro I¹, Lourenço O², Alves C¹, Thuresson P³, Monteiro I⁴, Batel-Marques F^1
1AIBILI, Coimbra, Portugal, ²University of Coimbra, Coimbra, Portugal, ³F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁴Roche Farmacêutica Química, Lda, Amadora, Portugal

PHS141-THE INCREASING IMPORTANCE OF A CONTINENCE NURSE SPECIALIST TO IMPROVE OUTCOMES AND SAVE COSTS OF URINARY INCONTINENCE CARE: AN ANALYSIS OF FUTURE POLICY SCENARIOS 

Los J, Corro-Ramos I, Franken M, Al M
Erasmus University Rotterdam, Rotterdam, The Netherlands

Best General Poster Research Presentations

PCV71 - RESOURCE UTILISATION AND COSTS IN PATIENTS WITH POST-STROKE SPASTICITY IN THE UNITED KINGDOM

Raluy-Callado M¹, Cox A¹, MacLachlan S¹, Gabriel S², Dinet J^2
1Evidera, London, UK, ²IPSEN Pharma, Boulogne-Billancourt, France

PCV50 - COMPARATIVE EFFECTIVENESS ON CARDIOVASCULAR OUTCOMES OF METFORMIN INITIAL THERAPY AND ADD-ON SECOND-LINE DRUGS AMONG PATIENTS WITH TYPE 2 DIABETES

Kim Y¹, Ko M¹, Jo A¹, Kang S¹, Tchoe H¹, Park C², Kim H¹, Choi J¹, Park D³, Lee W^3
1National Evidence based Health-care Collaborating Agency, Seoul, South Korea, ²National Evidence-based Health-care Collaborating Agency, Seoul, South Korea, ³Asan Medical Center, Seoul, South Korea

PRM137 - SCORING AND RESPONSIVENESS OF THE SELF-ASSESSMENT OF TREATMENT VERSION II QUESTIONNAIRE IN PATIENTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY

van Nooten FE¹, Trundell D², Staniewska D³, Revicki DA^3
1Astellas Pharma BV, Leiden, The Netherlands, ²Evidera, Inc., London, UK, ³Evidera, Bethesda, MD, USA

Best Student Poster Research Presentations

PSY95 - THE RELATIONSHIP BETWEEN DISEASE SEVERITY AND QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

Geale K¹, Henriksson M², Schmitt-Egenolf M^1
1Umeå University, Umeå, Sweden, ²Linköping University, Linköping, Sweden

PCV163 - ANGIOTENSIN CONVERTING ENZYME INHIBITORS PRESCRIBING PATTERN FOR DIFFERENT INDICATIONS: A POPULATION BASED STUDY

Mahmoudpour SH¹, Asselbergs FW², Souverein PC¹, de Boer A¹, Maitland-van der Zee A^1
1Utrecht University, UTRECHT, The Netherlands, ²University Medical Centre Utrecht, UTRECHT, The Netherlands

PCN260 - BURDEN OF METASTATIC RENAL CELL CARCINOMA IN FRANCE FROM 2008 TO 2013: ANALYSIS OF THE FRENCH NATIONAL HOSPITAL DATABASE

Maroun R¹, Maunoury F², Benjamin L¹, Nachbaur G¹, Durand-Zaleski I^3
1GSK France, Marly le roi, France, ²Statesia, Le Mans, France, ³URC Eco, Paris, France

Best New Investigator Poster Research Presentations

PDB79 - IMPACT OF A TELEPHONIC OUTREACH PROGRAM ON MEDICATION ADHERENCE IN MEDICARE ADVANTAGE PRESCRIPTION DRUG (MAPD) PLAN BENEFICIARIES

Park H, Adeyemi A, Roane T
University of Florida, Gainesville, FL, USA

PDB1 - RISK OF NEW-ONSET DIABETES ASSOCIATED WITH CONCOMITANT ANTIDEPRESSANT, INHALED CORTICOSTEROIDS, AND STATIN USE AMONG MEDICAID BENEFICIARIES WITH COPD

Ajmera MR¹, Sambamoorthi U^2
1RTI Health Solutions, RTP, NC, USA, ²West Virginia University, Morgantown, WV, USA

PUK11 - COST-CONSEQUENCES ANALYSIS OF FESOTERODINE AT FLEXIBLE-DOSE IN THE THERAPY OF OVERACTIVE BLADDER IN ROUTINE MEDICAL PRACTICE

Peral C¹, Rejas J², Ramos J¹, Sanchez-Ballester F³, Garcia-Mediero JM^4
1Pfizer S.L.U., Alcobendas (Madrid), Spain, ²Pfizer, Alcobendas, Spain, ³Department of Urology, Valencia, Spain, ⁴Hospital MD Anderson, Madrid, Spain

Economic evaluation of flexible-dose Fesoterodine, including two treatment groups, in the management of Overactive Bladder in routine clinical practice, from the Spanish NHS perspective.

PRS1-EFFECTS OF A CHRONIC OBSTRUCTIVE PULMONARY DISEASE INTEGRATED CARE PATHWAY PROGRAMME IN SINGAPORE 

Wu C, Gerald C, Tai KP
JurongHealth, Singapore, Singapore

PRS16-COMPARATIVE EFFECTIVENESS ANALYSIS FOR SMOKING CESSATION MEDICATIONS

Chang P¹, Lo P², Chang H², Hsueh K³, Tsai Y², Lan T^4
1Department of Medicine, Stanford University School of Medicine, California, CA, USA, ²Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan, ³Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁴Center for Geriatrics and Gerontology Taichung Veterans General Hospital, Taichung, Taiwan

PCV24-COST–EFFECTIVENESS OF DIFFERENT STRATEGIES FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT IN CHINA

Yan XY¹, Gu XH², Zhou L³, Lin HW⁴, Wu B^4
1Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China, ²Department of Respiratory, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China, ³Department of Cardiology, Renji Hospital, Shanghai, China, ⁴Medical Decision and Economic Group, Department of Pharmacy, Renji Hospital, Shanghai, China

PHP33-CONSTRUCTION OF SYSTEM DYNAMICS MODEL FOR MEDICAL CARE SYSTEM OF JAPAN

Inoue S¹, Xu H², Maswana J², Kobayashi M^1
1CRECON Medical Assessment Inc., Tokyo, Japan, ²University of Tsukuba, Tokyo, Japan

PSY18-THE ASSOCIATION WITH PSYCHIATRIC DISEASES AND PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA IN TAIWAN

Chang C¹, Chu C², Tang C^1
1Taipei Medical University, Taipei, Taiwan, ²National Taiwan University Hospital, Taipei, Taiwan

PMH8-ESTIMATING THE ECONOMIC BURDEN OF TREATMENT RESISTANT DEPRESSION IN TAIWAN USING THE NHIRD

Klug J¹, Yu F², Chang C³, Juang H⁴, Wang M⁵, Fife D⁶, Liu C⁴, Wang BC^7
1Janssen Asia Pacific, Kowloon, Hong Kong, ²Janssen Asia Pacific, Beijing, China, ³Chang Gung University, TaoYuan, Taiwan, ⁴Chang Gung Memorial Hospital, Tao-Yun, Taiwan, ⁵Janssen Taiwan, Taipei, Taiwan, ⁶Janssen, pharmaceutical company of Johnson and Johnson, Titusville, NJ, USA, ⁷Elysia Group Ltd, Taipei, Taiwan

PCN34 - QUALITY OF LIFE AMONG PATIENTS WITH ESOPHAGEAL/CARDIAC PRECURSOR LESION OR CANCER: A ONE-YEAR PROSPECTIVE SURVEY

Zhao Z, Pan X, Wen Y, Huang W, Chen F, Lan H, Huang H, Yang C
Sichuan University, Chengdu, China

PRM10 - HEALTH ECONOMICS METHODOLOGIES INVOLVING PARKINSON'S DISEASE TREATMENT IN CHINA

Low W¹, Azmi S¹, Yee SL¹, Milea D^2
1Azmi Burhani Consulting, Petaling Jaya, Malaysia, ²Lundbeck Singapore Pte Ltd., Singapore, Singapore

PMS10 - THE COSTS OF MAJOR AND MINOR CYCLING ACCIDENTS IN TASMANIA, AUSTRALIA

Palmer AJ, Si L, Gordon J
University of Tasmania, Hobart, Australia

PRM28 - A COMPARISON OF THREE LANGUAGE VERSIONS OF THE EQ-5D-5L DIMENSION SCALES IN SINGAPORE

Luo N¹, Wang Y¹, How C², Wong K¹, Tay E², Thumboo J^3
1Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, ²SingHealth Polyclinics, Singapore, Singapore, ³Singapore General Hospital, Outram, Singapore

PDB31 - DEMOGRAPHICS AND HEALTH OUTCOMES ASSOCIATED WITH ADHERENCE AND NON-ADHERENCE AMONG TYPE2 DIABETICS IN CHINA

Kumar M¹, Gupta S², Liu G³, Stankus AP^2
1Kantar Health, New York, NY, USA, ²Kantar Health, Princeton, NJ, USA, ³Peking University, Beijing, China

PCN2 - PROSTATE CANCER OVERALL SURVIVAL: MULTILEVEL ANALYSIS OF A POPULATION-BASED CANCER REGISTRY DATA

Xiao H¹, Tan F², Adunlin G¹, Ali AA¹, Goovaerts P³, Huang Y⁴, Gwede C^5
1Florida A&M University, Tallahassee, FL, USA, ²Indiana University-Purdue University, Indianapolis, IN, USA, ³BioMedware, Inc., Ann Arbor, MI, USA, ⁴Florida Department of Health, Tallahassee, FL, USA, ⁵Moffitt Cancer Center, Tampa, FL, USA

PCV1 - EVALUATION OF STATIN-ASSOCIATED ADVERSE EVENTS: ANALYSIS OF THE INCIDENCE AND INFLUENCE OF THE CONCOMITANT USE OF POTENTIAL INTERACTING DRUGS

Wang MT¹, Chiang PY², Lee WJ^3
1National Defense Medical Center, Taipei, Taiwan, ²Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ³School of Pharmacy, National Defense Medical Center, Taipei, Taiwan

PHP8 - FACTORS ASSOCIATED WITH UNNECESSARY USE OF ANTIBIOTICS IN U.S. STATE MEDICAID PROGRAMS

Li P¹, Marcus S², Metlay J¹, Doshi JA^1
1University of Pennsylvania, Philadelphia, PA, USA, ²Penn Social Policy & Practice, Philadelphia, PA, USA

PHP9 - ASSESSMENT OF DIAGNOSTIC NEED FOR MAGNETIC RESONANCE IMAGING IN MEDICARE PATIENTS WITH PACEMAKER IMPLANTS

Eggleston A¹, Lim M², Veath BK³, Mura T^4
1Medtronic International Ltd., North Ryde, NSW, Australia, ²Medtronic International Ltd., Singapore, Singapore, ³Medtronic International Ltd., Mounds View, MN, USA, ⁴Medtronic Japan Co Ltd, Tokyo, Tokyo, Japan

PHP20 - REAL-WORLD UTILIZATION PATTERN OF BIOLOGICS IN RHEUMATOID ARTHRITIS: A POPULATION-BASED STUDY

Liao CH, Wang YC, Chen JJ, Pwu RF
Center for Drug Evaluation, Taipei, Taiwan

PIH1 - PREGNANCY OUTCOMES AFTER MATERNAL EXPOSURE TO TOPICAL CORTICOSTEROIDS: A POPULATION-BASED COHORT STUDY

Chi CC¹, Wang SH², Mayon-White R³, Wojnarowska F^3
1Chang Gung Memorial Hospital-Chiayi, Chang Gung University College of Medicine, Puzih, Chiayi, Taiwan, ²Far Eastern Memorial Hospital, Oriental Institute of Technology, New Taipei, Taiwan, ³University of Oxford, Oxford, UK

PMH3 - CAREGIVER PERCEPTIONS ON THE BURDEN OF CARING FOR DEMENTIA PATIENTS: RESULTS FROM A CROSS-SECTIONAL HOSPITAL-BASED STUDY IN CHINA

Mould JF¹, Tang B¹, Harary E1, Kurzman R¹, Pan S1, Kaminsky R², Yang J^1
1Pfizer, New York, NY, USA, ²Boehringer Ingelheim, Hanover, Germany

PMS33: LONG-TERM WORK PRODUCTIVITY IMPROVEMENT FROM PHASE 3 BARICITINIB RA-BEAM STUDY: LATIN AMERICAN SUBGROUP ANALYSIS

Manny Papadimitropoulos, Eli Lilly and Company, Canada; University of Toronto, Toronto, ON, Canada

PMS4: COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND ADALIMUMAB IN ANKYLOSING SPONDYLITIS AS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON: AN ANALYSIS BASED ON ALL PIVOTAL PHASE 3 CLINICAL

Gustavo F. Rosal, Novartis Biociências SA, Sao Paulo, Brazil

PCN26: CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE

Luiza Vasconcelos Biglia, Student of Pharmacy-Biochemistry, Merck, São Paulo, Brazil

PMH2: AVALIAÇÃO DA REDUÇÃO DE REHOSPITALIZAÇÃO DOS PACIENTES COM ESQUIZOFRENIA, TRATADOS COM PALMITATO DE PALIPERIDONA

Benilda Luiza Klingelfus, Unimed Curitiba, Curitiba, Brazil

PMD24: COST-EFFECTIVENESS STUDY OF THE USE OF PORTABLE COAGULOMETERS FOR THE INR CONTROL, IN COMPARISON WITH HOSPITAL CARE, IN PATIENTS WITH COAGULATION DISORDERS, UNDER THE CONTEXT OF THE MEXICAN PUBLIC HEALTH SETTING

JA Reyes-Loredo, Roche, Mexico, Mexico 

PCN3: INTRACORPOREAL VERSUS EXTRACORPOREAL ANASTOMOSIS IN LAPAROSCOPIC RIGHT HEMICOLECTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Daiane Oliveira, Johnson & Johnson Medical Brazil, São Paulo, Brazil

PMD11 - COST-EFFECTIVENESS OF THE USE OF 18FDG-PET/CT IN THE DETECTION OF RECURRENT DIFFERENTIATED THYROID CANCER

Biz AN¹, Schluckebier LF², Bastos CR¹, Silva RM³, Braga JU¹, Caetano R^1
1Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Instituto Nacional do Câncer, Rio de Janeiro, Brazil, ³Escola Nacional de Saúde Pública Sergio Arouca FIOCRUZ, Rio de Janeiro, Brazil

PCN32 - PANITUMUMAB + MFOLFOX6 VERSUS BEVACIZUMAB + MFOLFOX6 AS FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER: A COST-EFFECTIVENESS ANALYSIS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

dos Santos RF¹, Coutinho MB², Haas L^3
1Amgen, São Paulo, Brazil, ²Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil, ³Sense Company, Rio de Janeiro, Brazil

PCN33 - COST-EFFECTIVENESS OF CERITINIB VERSUS CURRENT THERAPIES FOR CHEMOTHERAPY-EXPERIENCED ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS IN MEXICO

Balu S¹, Cerezo-Camacho O², Smith NJ³, Beckerman R^4
1Novartis Pharmaceuticals, East Hanover, NJ, USA, ²Novartis Farmaceutica, S.A.de C.V., Ciudad de Mexico, NJ, USA, ³CBPartners, New York, NY, USA, ⁴Maple Health Group, LLC, New York, NY, USA

PGI1 - ESTUDIO DE IMPACTO PRESUPUESTAL DE DACLATASVIR ASOCIADO A ASUNAPREVIR DESDE LA PERSPECTIVA DEL SISTEMA DE SALUD PUBLICO CHILENO

Vargas C¹, Giglio A², Soza A³, Espinoza MA^4
1Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Complejo Asistencial Sótero del Río, Santiago, Chile, ³Pontificia Universidad Católica de Chile, Santiago, Chile, ⁴Catholic University of Chile, Santiago, Chile

PCN16 - ESTIMATING THE BUDGET IMPACT OF SWITCHING FROM BORTEZOMIB INTRAVENOUS (IV) TO BORTEZOMIB SUBCUTANEOUS (SQ) IN THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) IN MEXICO

Wehler EA¹, Kowal S², Hernandez-Garduno A³, Danese de los Santos L³, de Anda JA⁴, Anaya P⁵, Munakata J⁶, Gonzalez-Michaca L^7
1IMS Health, Plymouth Meeting, PA, USA, ²IMS Health, Seattle, WA, USA, ³Janssen, Mexico City, Mexico, ⁴IMS Health, Mexico City, Mexico, ⁵IMS Health, México, D.F., Mexico, ⁶IMS Health, San Francisco, CA, USA, ⁷Janssen, Raritan, NJ, USA 

PCN45 - ANÁLISIS COSTO-UTILIDAD DEL MANEJO INTEGRAL DE LAS PACIENTES CON CARCINOMA DE SENO TRATADAS CON RECONSTRUCCION DE SENO INMEDIATA VS. DIFERIDA EN COLOMBIA

Perea-Bello AH¹, Rosselli D^2
1Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogotá, DC, Colombia, ²Pontifícia Universidade Javeriana, Bogotá, Colombia

PMS16 - COSTO-UTILIDAD DE COLÁGENA-POLIVINILPIRROLIDONA EN EL TRATAMIENTO DE OSTEARTROSIS DE RODILLA I-II FRENTE AL CUIDADO ESTANDAR ESTABLECIDO EN LOS PROTOCOLOS VIGENTES DE LAS INSTITUCIONES PUBLICAS EN MEXICO

Burbano-Levy X¹;Cardona DP²;Palacios E³;Rico-Alba I³, Zapata L^3
1Zilonis Health, Inc, Boca Raton, FL, USA, ²Universidad de Antioquia- Facultad De Quimica Farmaceutica, Medellín, Colombia, ³Guia Mark, S. A. de C. V., Mexico, DF., Mexico

PMH10 - NEEDS ASSESSMENT OF PATIENTS TREATED IN COMMUNITY PSYCHOSOCIAL CENTERS IN SÃO PAULO, BRAZIL

Nascimento A¹;Velasco TM², Oliveira MSC^1
1Faculdade de Ciências Medicas da Santa Casa de São Paulo, São Paulo, Brazil, 2Hospital Alemão Oswaldo Cruz, São Paulo, Brazil

PMH14 - STANDARDIZED TOOL FOR MEASUREMENT OF HEALTH SERVICES COSTS AND UTILIZATION IN A SAMPLE WITH MENTAL DISORDERS: TRANSLATION, CULTURAL ADAPTATION AND INTERRATER RELIABILITY OF THE CLIENT SOCIODEMOGRAFIC AND SERVICE RECEIPT INVENTORY BRAZILIAN VERSION

Sousa A;Cardoso A;Oliveira GG;Mari JJ, Razzouk D
Universidade Federal de Sao Paulo, SAO PAULO, Brazil

PND16 - BURDEN OF MULTIPLE SCLEROSIS AND UNMET NEEDS IN BRAZIL: MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE USING EQ-5D

Silva NL¹;Takemoto M²;Damasceno B³;Fragoso YD⁴;Finkelsztejn A⁵, Gomes M^1
1Novartis Biociências S.A., São Paulo, Brazil, ²ANOVA - Knowledge Translation, Rio de Janeiro, Brazil, ³UNICAMP - Hospital de Clínicas, Campinas, Brazil, ⁴UNIMES - Universidade Metr

PHP24 - ECONOMIC BURDEN OF INPATIENT POST-ADMISSION DEHYDRATION – RETROSPECTIVE DATABASE ANALYSIS IN US

Pash E;Hashemi L, Parikh N
Covidien, Mansfield, MA, USA

PGI2 - COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ARGENTINA

Garcia Marti S¹;Alcaraz A¹;Valanzasca P¹;Garay Ulises U¹;McMullen M¹;Rey Ares L¹;Peirano I²;Bessone F³;Fainboim H⁴;Gadano A⁵;Galdame O⁵;Vujacich C⁶, Caporale J^1
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, ²Jan